Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
AETIONOMY is a transnational collaborative medical research project funded by the European Union's Innovative Medicines Initiative (IMI). Its core goal is to break through the limitations of traditional disease definitions, identify molecular features for two neurodegenerative diseases — Alzheimer's disease and Parkinson's disease, establish a precision medicine-oriented disease classification framework, and provide the research field with reusable standardized research data and analysis tools.
The project's core outputs fall into two main categories: First, the AETIONOMY Knowledge Base (AKB), which integrates scattered clinical and omics data generated by different studies over the years, completes data cleaning and standardization, and builds an integrated platform based on the tranSMART system. It supports researchers in accessing data and conducting online computational analysis of results. Second, the NeuroMMSig tool, built on a knowledge base of neurodegenerative disease pathological mechanisms, supports mechanistic interpretation and enrichment analysis for multi-scale, multi-modal clinical data, helping researchers identify pathological associations from their datasets.
Advantages: The project was jointly completed by top-tier academic institutions including the Fraunhofer Institute and pharmaceutical companies. The quality of its integrated data is far higher than scattered publicly available data, and all resources are completely free for academic research, greatly lowering the cost of data access for relevant studies. Its preliminary differentiated patient stratification has also opened up clear new research directions for the field.
Disadvantages: The project's core work was completed in 2018, with no continuous updates afterward, so it does not incorporate new research data generated in recent years. It is also designed exclusively for professional researchers, with no use cases for general users, and its commercial licensing terms are unclear.
The main website can be accessed directly from Chinese networks, and the core data platform also loads normally. It is well-suited for research teams working in the neurodegenerative disease field around the world.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on aetionomy.eu official site.
aetionomy.eu is an EU Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach aetionomy.eu directly.